Orthofix Names Andres Cedron as New Chief Legal Officer

LEWISVILLE, Texas, April 16, 2024–(BUSINESS WIRE)–Orthofix Medical Inc. (NASDAQ:OFIX), a number one international spine and orthopedics firm, right this moment introduced that Andres Cedron has joined the corporate as Chief Authorized Officer.

Cedron most lately served as Vice President and Company Secretary at Stryker Company, a $20B+ international medical gadget firm. In his company officer place, Cedron oversaw Stryker’s company governance, SEC compliance, mergers and acquisitions, and ESG issues.

“With a broad breadth of expertise within the medical gadget business and authorized transactions, Andres is the proper match for this essential management function,” stated Massimo Calafiore, President and Chief Government Officer of Orthofix. “His in depth understanding of our enterprise and the general market might be an asset in serving to the corporate drive profitability and development as we proceed to energy Orthofix’s transformation.”

Cedron is understood for his sturdy concentrate on scaling companies and accelerating efficiency and can lead Orthofix in a broad vary of company and business issues.

“I’m thrilled to affix such a proficient management workforce and group of devoted staff,” stated Andres Cedron, Chief Authorized Officer. “That is an thrilling time for the corporate, and I look ahead to serving to Orthofix grow to be an excellent stronger competitor out there.”

About Andres Cedron

Cedron brings almost 20 years of govt authorized expertise to Orthofix. Along with his function as Vice President and Company Secretary at Stryker, Cedron held management roles as Chief Authorized Counsel for Stryker’s $10B+ MedSurg and Neurotechnology Group, in addition to the corporate’s EMEA and Latin America areas. As well as, Cedron served as President of Stryker’s Hispanic/Latino worker useful resource group from 2019 to 2022, rising it from two to eight chapters nationally and greater than 1,000 members. He has in depth experience in regulatory and compliance frameworks, anti-corruption packages, litigation administration, and business authorized methods within the medical gadget business.

Earlier than Stryker, Cedron began his profession as a company lawyer at legislation corporations in New York and Miami. Cedron holds a J.D. from Columbia Regulation Faculty and a B.A. from Colorado Faculty.

As an inducement to enter into employment with Orthofix, Cedron was granted (i) performance-based vesting restricted inventory models that settle 57,296 shares of widespread inventory at goal achievement, (ii) time-based vesting restricted inventory models that settle into 28,648 shares of widespread inventory, and (iii) inventory choices to buy 64,817 shares of widespread inventory. The performance-based vesting restricted inventory models vest on the finish of a three-year efficiency interval based mostly on the Firm’s whole stockholder return relative to an business peer group index throughout such interval, whereas the time-based vesting restricted inventory models vest in equal tranches over three years. The inventory choices vest upon achievement of each service- and performance-based standards, whichever is the later of (a) the date sure service-based circumstances are met (which might be met over three years) and (b) the date that the common closing value of the Firm’s widespread inventory over a one-month calendar interval has been equal to or nice than 150% of the closing value of the Firm’s widespread inventory on the grant date. The grants, which have been authorized by Orthofix’s Board of Administrators, have been made underneath standalone inducement award agreements authorized pursuant to NASDAQ Market Rule 5635(c)(4).

About Orthofix

Orthofix is a number one international spine and orthopedics firm with a complete portfolio of biologics, progressive spinal {hardware}, bone development therapies, specialised orthopedic options, and a number one surgical navigation system. Its merchandise are distributed in additional than 60 nations worldwide.

The Firm is headquartered in Lewisville, Texas, the place it conducts normal enterprise, product growth, medical training and manufacturing, and has major workplaces in Carlsbad, CA, with a concentrate on spine and biologics product innovation and surgeon training, and Verona, Italy, with an emphasis on product innovation, manufacturing, and medical training for orthopedics. The mixed Firm’s international R&D, business and manufacturing footprint additionally contains services and workplaces in Irvine, CA, Toronto, Canada, Sunnyvale, CA, Wayne, PA, Olive Department, MS, Maidenhead, UK, Munich, Germany, Paris, France and São Paulo, Brazil.

Ahead-Wanting Statements

This information launch could embrace forward-looking statements inside the which means of Part 21E of the Securities Alternate Act of 1934, as amended, and Part 27A of the Securities Act of 1933, as amended. In some circumstances, you may determine forward-looking statements by terminology equivalent to “could,” “will,” “ought to,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “initiatives,” “intends,” “predicts,” “potential,” “proceed” or different comparable terminology. Orthofix cautions you that statements included on this information launch that aren’t an outline of historic details are forward-looking statements which might be based mostly on the Firm’s present expectations and assumptions. Every forward-looking assertion contained on this information launch is topic to dangers and uncertainties that might trigger precise outcomes to vary materially from these expressed or implied by such assertion. Relevant dangers and uncertainties embrace, amongst others: the power of newly launched merchandise to carry out as designed and meant and to satisfy the wants of surgeons and sufferers, together with because of the dearth of strong scientific validation; and the dangers recognized underneath the heading “Threat Components” in Orthofix Medical Inc.’s Annual Report on Kind 10-Ok for the fiscal 12 months ended December 31, 2023, which was filed with the Securities and Alternate Fee (SEC) on March 5, 2024. The Firm’s public filings with the Securities and Alternate Fee can be found at www.sec.gov. You’re cautioned to not place undue reliance on forward-looking statements, which communicate solely as of the date when made. Orthofix doesn’t intend to revise or replace any forward-looking assertion set forth on this information launch to mirror occasions or circumstances arising after the date hereof, besides as could also be required by legislation.